让新药好药“买得到、用得上、能报销”

Core Insights - The new national medical insurance negotiation drug directory has been officially implemented since January 1, aiming to enhance the accessibility and affordability of innovative drugs for patients [1][2] Group 1: National Drug Directory Changes - The updated directory includes 114 new drugs, of which 50 are first-class innovative drugs, while 29 drugs have been removed due to lack of supply or better alternatives [1] - The adjustments significantly improve coverage for critical areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [1] Group 2: Implementation and Collaboration - Medical institutions are required to incorporate the national negotiation drugs into their procurement lists within one month of the directory's release, with Suzhou hospitals actively responding to this mandate [2] - The Suzhou Medical Insurance Bureau organized a collaborative meeting to facilitate communication among healthcare, medical insurance, and pharmaceutical sectors, involving over 100 participants from various institutions [2][3] Group 3: Innovative Approaches in Hospitals - Hospitals in Suzhou are adopting innovative measures, such as establishing intelligent medication review systems and a three-dimensional access mechanism for drug evaluation, to streamline the process of incorporating national negotiation drugs [2] - The total settlement amount for national negotiation drugs in Suzhou is projected to increase from 1.44 billion yuan in 2023 to 1.59 billion yuan in 2025 [2] Group 4: Future Developments - By 2025, Suzhou is expected to have 18 innovative drugs included in the new directory, with 14 in the national basic medical insurance directory and 4 in the commercial insurance innovative drug directory [3] - A dual-channel supply guarantee system has been established to provide patients with diverse and convenient purchasing options for innovative drugs [3][4]